CAS:1797008-57-1|Crenolanib Trifluoroacetic Acid Salt

CAS:1797008-57-1|Crenolanib Trifluoroacetic Acid Salt

Catalogue Number:C781800
Chemical Name:Crenolanib Trifluoroacetic Acid Salt
Synonyms:1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine Trifluoroacetic Acid Salt; ARO 002 Trifluoroacetic Acid Salt; CP 868596 Trifluoroacetic Acid Salt; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine Trifluoroacetic Acid Salt;
CAS Number:1797008-57-1
Alternate CAS #
Free amine: 670220-88-9
Molecular Formula:C₂₈H₃₀F₃N₅O₄
Appearance:Off-White to Pale Yellow Solid
Melting Point:214-217°C
Molecular Weight:557.56
Storage:4°C
Solubility:DMSO (Slightly), Methanol (Very Slightly)
Category:Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
Applications:Crenolanib (CP-868569) is a tyrosine kinase inhibitor that acts by specifically inhibiting the receptor tyrosine kinases PDGFRa and PDGFRb. Crenolanib (CP-868569) inhibits the activity of PDGFRa D842V kinase and prevented the phosphorylation of wild type PDGFRa. Crenolanib (CP-868569) possesses potential antineoplastic activity. Crenolanib is believed to suppress PDGFR-related signal transduction pathways leading to the inhibition of tumor angiogenesis and tumor cell proliferation.
References:Michael, M. et al.: Br. J. Cancer, 103, 1554 (2010); Lewis, N.L. et al.: J. Clin. Oncol., 27, 5262 (2009);
To ensure the stability of our products, the efficient express delivery service will be used. We also guarantee that the products will be shipped in the box with layers of tapes to protect them against damage. The extremely low temperature products will be wrapped with dried ice, and the low temperature products will be delivered with ice bags. As for the products stored at room temperature, they will not be packed with ice bags or dried ice. Taskcm is committed to providing cost-effective products that facilitate drug delivery with our customers.
Email:sales@ebclink.com

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *